Filing Flows › Health Care › CV Sciences (CVSI)
CV Sciences (CVSI) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · CV Sciences (CVSI) Q2 2026 earnings results →
Q2 2026 Revenue down 18% year over year to $3.0M · 26¢ of every $1 of revenue lost · operating margin -10.1%
CV Sciences made $3.0M in Q2 2026 (-18% Y/Y). Operating margin -10.1%, net loss $775K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $3.0M in Q2 2026, down 18% year over year and down 7% from the previous quarter.
Gross margin was 48.6%, down 2.4 points from Q2 2025. Operating costs exceeded revenue by $301K, an operating margin of -10.1%. Operating expenses fell 11% while revenue fell 18%. The quarter ended with a net loss of $775K, wider than the previous quarter's $643K loss. Net interest and other expense of $469K was the main reason.
Operating cash flow was $20K (down 93% year over year). Non-cash charges added back $22K of depreciation and amortization and $148K of share-based compensation. Working capital and other items added $625K. Capital expenditures of $7K left free cash flow of $13K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $3.0M | -18% | -10.1% | −$775K | $20K |
| Q1 2026 | 10-Q | May 15, 2026 | $3.2M | -11% | -10.0% | −$643K | $101K |
| Q4 2025 | 10-K | Mar 26, 2026 | $3.3M | -15% | -2.3% | −$206K | −$354K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $3.3M | -16% | -8.4% | −$382K | −$259K |
| Q2 2025 | 10-Q | Aug 13, 2025 | $3.6M | -8% | -3.6% | −$261K | $287K |
| Q1 2025 | 10-Q | May 14, 2025 | $3.6M | -10% | 0.3% | −$109K | −$81K |
| Q4 2024 | 10-K | Mar 27, 2025 | $3.9M | +2% | -16.6% | −$726K | −$164K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About CV Sciences
CV Sciences, Inc. (“CV Sciences,” the “Company,” “we,” “our” or “us”) is a consumer wellness company specializing in nutraceuticals and plant-based foods. Our hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (“B2B”) to business-to-consumer (“B2C”). Our +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling brands of hemp extracts in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, +PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov.
In its own words, from its 10-K, filed Mar 26, 2026.
CV Sciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -18% against the peers' median +7%. Operating margin: -10.1% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CVSI CV Sciences | Q2 2026 | $3.0M | -18% | -10.1% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: CV Sciences 10-Q on SEC EDGAR · CIK 1510964 · Pharmaceutical Preparations
More on CVSI
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results